Plus Therapeutics Q1 net loss $6.9M; REYOBIQ gets FDA Orphan Drug Designation

PLUS THERAPEUTICS, INC.

Cash and investments $15.1M as of March 31, 2026, up from $8.6M at Dec 2025 after $15M public offering.
Net loss $6.9M ($1.05 per share) vs $17.4M in Q1 2025 (post reverse split).
Revenue $1.0M from CPRIT grant and CNSide billings; operating loss $7.1M vs $3.5M year ago.
FDA granted Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas and ependymoma.
CNSide expanded payer coverage to ~81M lives including Blue Shield of California; unique PLA code secured.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.